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a b s t r a c t
Background: To describe the national trends and outcomes of contemporary thrombectomy use for primary percutaneous coronary intervention (PCI) from 2016 to 2018.
Methods: We queried the Nationwide Readmission Database (NRD) from January 2016 to December 2018 to
identify patients who underwent primary PCI and thrombectomy. We conducted a multivariate regression analysis to identify variables associated with in-hospital mortality and stroke in patients undergoing primary PCI and
those who underwent thrombectomy.
Results: We identiﬁed 409,910 total hospitalizations who underwent primary PCI. Thrombectomy was used in
62,446 records (15.2%) with no change in the trend over the study period (p trend = 0.52). Thrombectomy
was more utilized in patients who had more cardiogenic shock and use of mechanical circulatory devices. The
overall incidence of in-hospital mortality and stroke were 5.6% and 1.1%, respectively. The incidence of inhospital mortality (6.7% vs. 5.4%, p < 0.001) and strokes (1.3% vs. 1.0%, p < 0.001) were higher in the
thrombectomy group. On multivariable regression analysis adjusting for high-risk features, thrombectomy was
not independently associated with in-hospital mortality [1.036, 95% CI (0.993–1.080), p = 0.100], but was associated with a higher risk of stroke [OR 1.186, 95% CI (1.097–1.283), p < 0.001].
Conclusion: During primary PCI, thrombectomy was used in 1 of 6 cases, and its use has been stable over
2016–2018. The use of thrombectomy was associated with a higher risk of stroke, but not in-hospital death.
© 2021 Elsevier Inc. All rights reserved.

1. Introduction
The presence of large thrombus burden in patients presenting with
ST-elevation myocardial infarction (STEMI) remains a challenge in contemporary interventional cardiology practice. Patients with large
thrombus burden undergoing primary percutaneous coronary intervention (PCI) experience higher rates of distal embolization, slow- or no-

Abbreviations: PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
⁎ Corresponding author at: Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202,
United States of America.
E-mail address: kalaswa1@hfhs.org (K. Alaswad).

reﬂow with resultant clinical deterioration, and worse in-hospital and
long-term outcomes [1].
There are multiple pharmacological and mechanical measures to deal
with large thrombus burden. Thrombus aspiration (thrombectomy) mechanically removes the thrombus using different tools (manual or
mechanical). In theory, thrombectomy works by reducing distal embolization and improving microvascular perfusion leading to improved
outcomes by avoiding the no-reﬂow phenomenon [2]. Initial studies
have shown improved outcomes (cardiac death and non-fatal MI) with
thrombus aspiration [3,4], but has been challenged by multiple randomized controlled trials (RCTs) demonstrating no clinical beneﬁt of routine
use of thrombectomy with possible signals for harm due to increased risk
of stroke [5,6,7].
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3. Results

Despite the recent guidelines downgrading routine use of
thrombectomy during PCI to class IIb or III [8,9], thrombectomy remains
a useful strategy for treating high-risk lesions with large thrombus burden [10]. Secemsky et al. investigated the National Cardiovascular Data
Registry (NCDR) CathPCI registry and showed the decline in manual
thrombectomy use from 2011 to 2016 [11]. We performed a comprehensive analysis of the Nationwide Readmissions Database (NRD) to describe the national trends and outcomes of thrombectomy use during
primary PCI between 2016 and 2018.

3.1. Patients and hospitals characteristics
We identiﬁed 409,910 total weighted hospitalizations who
underwent primary PCI for STEMI after excluding patients with missing
data on in-hospital mortality (Fig. S1). Thrombectomy was used in
62,446 records (15.2%). Over the study period, there was no signiﬁcant
change in the trends of thrombectomy use (15% in the ﬁrst quarter of
2016 and 14.6% in the last quarter of 2018), p = 0.524 (Fig. 1). The
total annual hospital volume of thrombectomy was highly variable,
with a median annual volume of 38 procedures [IQR 21–68]. Highvolume thrombectomy hospitals were deﬁned as those hospitals
performing procedures above the 90th percentile of volumes (≥110
thrombectomy procedures a year) (Fig. S2).
Baseline characteristics of the included patients are shown in
Table S2. The median patient age was 62 (IQR 54–71) years, and 28.8%
were women. Of these patients, about 39.6% presented with anterior
STEMI. PCI of bifurcation lesions occurred in 3.1%, and multivessel PCI
in 15.4%. Impella was used in 2.3% and intra-aortic balloon pump
(IABP) was used in 7.1% of cases. Intravascular imaging was used in
6.1% of cases.
Patients who underwent thrombectomy were younger (61 vs. 62
years, p < 0.001) and less likely to be female (25.7% vs. 29.3%, p <
0.001). Thrombectomy was more utilized in patients with atrial ﬁbrillation or ﬂutter (13.4% vs. 11.8%, p < 0.001), chronic total occlusion (9.3%
vs. 8.2%, p < 0.001), congestive heart failure (1.5% vs. 1.4%, p < 0.001),
prior myocardial infarction (13.5% vs. 12.1%, p < 0.001), acute stent
thrombosis (7.6% vs. 2.4%, p < 0.001), and bifurcation lesions (3.4% vs.
3%, p < 0.001) (Table S2). Mechanical circulatory devices [Impella, IABP,
and extracorporeal membrane oxygenation (ECMO)] were more reported
in patients who underwent thrombectomy (Table 1). Thrombectomy was
less utilized in patients presenting with anterior STEMI (38% vs. 39.9%, p <
0.001) and multivessel PCI (13.6% vs. 15.7%, p < 0.001).

2. Methods
2.1. Data source
We used the Nationwide Readmissions Database (NRD), Healthcare
Cost and Utilization Project (HCUP), Agency for Healthcare Research
and Quality to obtain our cohort. The NRD contains discharge data
from 28 geographically dispersed States, accounting for 60% of the
total U.S. resident population and 58.2% of all U.S. hospitalizations. We
identiﬁed our cohort, procedures, and outcomes using the International
Classiﬁcation of Diseases, Tenth Revision, Clinical Modiﬁcation (ICD 10
CM) and procedure (ICD 10-PCS) codes along with ICD-10 clinical classiﬁcation codes (CCS). The codes used are summarized in Table S1.
2.2. Study population
We identiﬁed our cohort using the ICD 10 codes for thrombectomy
during primary PCI for years 2016 to 2018 (Table S1). Patient and
hospital-level variables provided by HCUP NRD were used to identify
demographics and baseline characteristics. The Elixhauser method
was used to assess comorbidities [12]. The rest of the comorbidities
were identiﬁed using appropriate ICD 10 CM codes (Table S1). We excluded patients with missing data on in-hospital mortality. The NRD is
a publicly available database with de-identiﬁed hospitalization records;
therefore, institutional review board approval was not required.

3.2. Outcomes
2.3. Outcomes
Study outcomes are summarized in Table 1. The overall incidence of
in-hospital mortality and stroke were 5.6% and 1.1%. The incidence of inhospital mortality (6.7% vs. 5.4%, p < 0.001) and stroke (1.3% vs. 1.0%, p
< 0.001) were higher in the thrombectomy group.
The risk of ischemic stroke, hemorrhagic stroke, and combined ischemic and hemorrhagic strokes were 0.9%, 0.3%, and 0.1%, respectively.
All subtypes of strokes were higher in the thrombectomy group. Patients who underwent thrombectomy had a higher incidence of cardiogenic shock, cardiac arrest, ventricular tachycardia, and complete
atrioventricular block. The length of stay was longer, and the cost of
index hospitalization was higher in patients who underwent
thrombectomy (Table 1).
On multivariable regression analysis adjusting for all high-risk features in Table S3, there was no association between thrombectomy
and in-hospital mortality [1.036, 95% CI (0.993–1.080), p = 0.100].
However, thrombectomy was associated with a higher risk of stroke
[OR 1.186, 95% CI (1.097–1.283), p < 0.001].
On multivariate regression analysis within the cohort of patients who
underwent thrombectomy, thrombectomy performed at a highervolume hospital (above the 90th percentile in thrombectomy volume)
was associated with lower incidence of all-cause mortality [OR 0.816,
95% CI (0.716–0.929), p = 0.002], and was not associated with an increased risk of stroke [OR 1.046, 95% CI (0.835–1.311), p = 0.694].
The summary of the study results is shown in Fig. 2.

The primary outcomes of our study were in-hospital mortality and
stroke. Secondary outcomes included vascular complications, renal
complications, discharge to a nursing facility, length of hospital stay,
and the cost of the index hospitalization.
2.4. Statistical analysis
All analyses were conducted using the appropriate weighting, stratifying, and clustering samples following HCUP regulations [13,14].
Given the lack of essential variables that would be required for adequate
matching (e.g., lesion complexity, thrombus burden, etc.), we did not
perform propensity-score matching. Categorical variables are displayed
as numbers and percentages and compared with Pearson's chi-square
or Fisher's exact tests. Continuous variables are summarized as medians
and interquartile range (IQR) (25th and 75th percentiles) and compared with the Mann-Whitney U test. All p-values are 2-sided with a
signiﬁcance threshold<0.05. The trend analysis was performed using
the linear regression method.
We performed multivariable regression analysis to identify variables
associated with in-hospital mortality and stroke in patients undergoing
primary PCI. We included all variables considered signiﬁcant based on
background knowledge using the “Enter” method. We then performed
multivariable regression analysis to identify variables associated with
in-hospital mortality and stroke in the cohort of patients who underwent
thrombectomy. We included annual hospital thrombectomy volume as a
variable in the regression analysis for the thrombectomy cohort. Statistical analysis was performed using IBM SPSS Statistics for Windows
(version 25.0. Armonk, NY: IBM Corp).

4. Discussion
The main ﬁndings of the study can be summarized as follows:
1) Over the years 2016–2018, thrombectomy was used in 15.2% of
2
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Fig. 1. Trends of thrombectomy use during primary percutaneous coronary intervention in the Nationwide Readmissions Database.

high-volume centers was associated with a lower incidence of inhospital mortality and was not associated with an increased risk of
stroke.
Thrombus aspiration during primary PCI remains one of the controversial treatment modalities in interventional cardiology. Previous studies have shown a controversial impact on the long-term outcomes,
including major adverse events (MACE) and cardiac death [3,4,5,6,7].
These studies have been heterogeneous in multiple aspects, including

cases during primary PCI, and the trend has been stable, 2) Patients who
had thrombectomy were higher risk with a higher incidence of cardiogenic shock, cardiac arrest, and use of mechanical circulatory support
devices, 3) patients who received thrombectomy had a higher incidence
of death and stroke, 4) after adjusting for high risk features,
thrombectomy was not independently associated with a higher risk of
death but associated with a higher risk of stroke, and 5) within the cohort of patients who underwent thrombectomy, thrombectomy at

Table 1
Summary of the study outcomes.

In-hospital mortality, n (%)
Discharge to a facility, n (%)
Neurological complications
All strokes, n (%)
Ischemic stroke, n (%)
Hemorrhagic stroke, n (%)
Mixed (ischemic and hemorrhagic strokes), n (%)
Transient ischemic attack, n (%)
Cardiac complications
In-hospital CABG, n (%)
Tamponade, n (%)
Cardiogenic shock, n (%)
Cardiac arrest, n (%)
Coronary perforation, n (%)
Coronary dissection n (%)
Ventricular tachycardia, n (%)
Complete atrioventricular block, n (%)
Impella, n (%)
ECMO, n (%)
Intra-aortic balloon, n (%)
Renal complications
Acute kidney injury requiring hemodialysis, n (%)
Vascular complications
Vascular complications requiring surgery, n (%)
Vascular complication, n (%)
Postprocedural bleeding, n (%)
Length of stay and cost
LOS, (median, IQR and mean ± SD) (days)
Cost, median (IQR) (dollars)

Overall (409,910)

Thrombectomy (n = 62,446)

No thrombectomy (n = 347,464)

P-value

22,889 (5.6%)
26,076 (6.4%)

4022 (6.7%)
4104 (6.6%)

18,867 (5.4%)
21,972 (6.3%)

<0.001
0.010

4427 (1.1%)
3523 (0.9%)
1120 (0.3%)
216 (0.1%)
634 (0.2%)

818 (1.3%)
631 (1%)
242 (0.4%)
55 (0.1%)
97 (0.2%)

3690 (1%)
2892 (0.8%)
877 (0.3%)
161 (<0.1%)
537 (0.2%)

<0.001
<0.001
<0.001
<0.001
0.960

9252 (2.3%)
1055 (0.3%)
51,617 (12.6%)
45,110 (11%)
1145 (0.3%)
4575 (1.1%)
52,321 (12.8%)
12,366 (3%)
9565 (2.3%)
158 (<0.1%)
29,252 (7.1%)

1361 (2.2%)
158 (0.3%)
10,227 (16.4%)
7934 (12.7%)
202 (0.3%)
663 (1.1%)
9600 (15.4%)
2708 (4.3%)
1962 (3.1%)
37 (0.1%)
6185 (9.9%)

7891 (2.3%)
898 (0.3%)
41,390 (11.9%)
37,176 (10.7%)
943 (0.3%)
3912 (1.1%)
42,721 (12.3%)
9658 (2.8%)
7603 (2.2%)
121 (0%)
23,067 (6.6%)

0.160
0.830
<0.001
<0.001
0.020
0.170
<0.001
<0.001
<0.001
<0.001
<0.001

4043 (1%)

691 (1.1%)

3353 (1%)

<0.001

100 (0%)
357 (0.1%)
4988 (1.2%)

16 (0%)
57 (0.1%)
822 (1.3%)

84 (0%)
301 (0.1%)
4166 (1.2%)

3 (2–4)
21,124 (16,116-30,320)

3 (2–4)
23,141 (17,413-34,049)

2 (2–4)
20,794 (15,926-29,703)

0.780
0.720
0.001
<0.001
<0.001

IQR: interquartile range; MI: Myocardial infarction; CABG: Coronary artery bypass graft; LOS: length of stay; OR: odds ratio; CI: conﬁdence interval; SD: standard deviation, ECMO: extracorporeal membrane oxygenation.
3
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Fig. 2. Summary of the study results.

of stroke during 1-year follow-up after routine thrombectomy [7]. A
substudy of the TOTAL trial showed that the difference in stroke was apparent within the ﬁrst 48 h after the procedure (0.3% versus 0.1%) [16].
The primary proposed mechanism of stroke is when the thrombus is
not fully aspirated or withdrawn intact into the guide catheter, leading
to further thrombus fragmentation, and shedding into the bloodstream.
This is more likely to occur with a high thrombus burden and if the suction could not be maintained on the thrombectomy catheter [17]. Other
mechanisms, including excess manipulation of the guide catheter or increased platelet reactivity after thrombectomy, are less likely to explain
the higher stroke risk with thrombectomy [18]. In our study, with multivariate regression analysis adjusting for higher-risk features,
thrombectomy remained associated with a higher risk of Stroke. Our contemporary cohort should reﬂect the improved operators' experience with
thrombectomy devices and the caution to maintain suction throughout
the thrombectomy procedure until the device is out of the body. However, the risk of stroke with thrombectomy remains real and consistent
with previous RCTs. There is a possibility that the occurrence of stroke is
independent of the technique and could be related to other factors
(e.g., excessive antithrombotic therapies with high thrombus burden
leading to more hemorrhagic strokes). The higher risk of hemorrhagic
stroke with manual thrombectomy has been previously shown in a
substudy of the TOTAL trial [16].
Within patients who underwent thrombectomy, our study showed
that performing thrombectomy in high-volume centers was associated
with a lower risk of death without an increased risk of stroke. Better outcomes with thrombectomy in high-volume sites could be related to the
presence of high-volume operators. Other technical aspects of the manual thrombectomy might also explain why high-volume centers might
have better outcomes. Deep guide catheter engagement during manual
thrombectomy might prevent dragging the thrombus into the aortic

the types of thrombectomy devices used and thrombus burden
reporting. As recent RCTs showed no beneﬁt in long-term outcomes,
routine thrombectomy recommendations have been incrementally
downgraded to class III in both American and European guidelines
[8,9]. However, room was given for thrombectomy use in patients
with large residual thrombus burden after initial ballooning (Class IIb).
In our study, despite the guidelines' recommendations,
thrombectomy was used in nearly 1 of 6 primary PCI cases from
2016 to 2018, with a stable trend over the three years. Our study
showed a higher rate of using thrombectomy (15%) compared with
the NCDR CathPCI database (<5%) [11]. This is likely due to the differences in the databases with the NRD capturing >50% of the hospitals in the United States, including those not reporting to the NCDR
CathPCI. The high use of thrombectomy in our study can be
interpreted in multiple ways. First, there is a general acceptance
that thrombectomy should not be routinely used, reﬂected in the relatively small percentage of its use (15.2%). Second, this also reﬂects
that interventional cardiologists apply their clinical judgment and
selectively use thrombectomy in higher thrombus burden or bailout
situations. Our analysis showed that patients who underwent
thrombectomy had a higher incidence of adverse outcomes, including cardiogenic shock, cardiac arrest, ventricular tachycardia, stroke,
and in-hospital death. These features might reﬂect the use of
thrombectomy in patients with higher-risk features, including
higher thrombus burden, late presentation, and hypercoagulable
states like cancer and diabetes. Previous studies have shown that
massive intracoronary thrombus has been reported in 16.4% of patients with acute coronary syndromes [15], which corresponds to
the rate of use of thrombectomy in our real-world study.
The most feared complication of thrombectomy use is the occurrence
of stroke, demonstrated in the TOTAL study, which showed a higher risk
4
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ﬂow and stroke. Less experienced operators are less likely to perform
deep guide catheter engagement. Application of continuous mechanical
aspiration during thrombectomy procedure might also prevent the release of thrombus fragments into the aortic blood ﬂow. The Indigo System CAT RX mechanical thrombectomy applies continuous vacuum
suction compared to manual suction. The powerful suction may overcome the main Achilles heel of manual thrombectomy which is diminished aspiration force as ﬂuid ﬁlls in the syringe, leading to potential
systemic embolization and increased stroke risk [7]. The initial experience with the Indigo CAT RX system was reported on 59 patients. It
showed a TIMI III ﬂow in 93.2% of patients with a median aspiration
time of 35 s and zero stroke incidences [19]. Multiple studies using
different mechanical thrombectomy devices did not demonstrate beneﬁt of mechanical thrombectomy during primary PCI. However, the
Indigo CAT RX system might be different given its superior suction
power [20]. The prospective, multicenter U.S. (CHEETAH) study
(NCT03957473) would provide more information on mechanical
thrombectomy's safety and efﬁcacy in patients with a high-thrombus
burden.
Despite the current controversy, thrombectomy remains a practical
tool during primary PCI. A recent patient-level meta-analysis demonstrated that routine thrombectomy did not improve clinical outcomes.
Still, there was a trend towards reduced cardiac death in the high
thrombus burden group, but at the expense of increased stroke risk
[21]. The most recent 2018 European guidelines on myocardial revascularization acknowledged the absence of data on thrombectomy's current beneﬁts, labeling the topic as a knowledge gap requiring more
studies, especially with the newer mechanical thrombectomy devices
available [22]. The Indigo CAT RX system might not be reﬂected on
our data as it was approved in April 2018. However, our results still emphasize the need to conﬁrm the safety of thrombectomy in contemporary practice and encourage further randomized trials.
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